Medtronic (Minneapolis) shook up the medical technology world on Sunday with news of a mega-sized deal to acquire rival Covidien (Dublin, Ireland) for $42.9 billion in cash and stock. The transaction also will allow Medtronic to reincorporate in Ireland, where Covidien is located, thus lowering its tax burden. Interestingly, the deal is contingent on there being no new laws or regulatory actions that would make such inversion deals illegal or prevent Medtronic from capitalizing on Covidien's lower tax rate. Read More
